GNI's pirfenidone set for Chinese launch for IPF
This article was originally published in Scrip
Executive Summary
GNI Group has overcome one of the main remaining hurdles to the commercialization of its antifibrotic agent pirfenidone (F647) for adult idiopathic pulmonary fibrosis (IPF) in China, receiving an important regulatory approval for its Beijing Continent Pharmaceuticals subsidiary.